 Biofrontera AG NASDAQ: BFRA; Frankfurt Stock Exchange: B8F the Company, an international biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency EMA has issued a positive opinion with respect to Biofronteras submission for label extension for its topical prescription drug Ameluz. The extended approval will include photodynamic therapy PDT of mild and moderate actinic keratoses AK on the extremities and trunkneck. 